Targeted Oncology reviews trending news online for the week of September 18, 2020, including updates in oncology, and new information regarding COVID-19.
This week, the FDA granted a Fast Track designation to the novel androgen receptor EPI-7386 as treatment of adult patients with metastatic castration-resistant prostate cancer who are resistant to standard of care treatment. A Breakthrough Therapy designation was also granted to magrolimab as treatment of patients with newly diagnosed myelodysplastic syndrome.
The Society of Hematologic Oncology (SOHO) hosted its eighth annual virtual meeting, in which attendance nearly doubled compared with previous years. The meeting focused on a theme of Molecular Classification and Precision Therapy with more than 150 presentations on a variety of hematologic malignancies.
Check out conference coverage from the ESMO Virtual Congress 2020.
Nathan A. Pennell, MD, PhD, discussed the case of 66-year-old patient with EGFR-mutant non–small cell lung cancer, during a virtual Case Based Peer Perspectives event.
In an interview with Targeted Oncology, Sara A. Hurvitz, MD, reviewed the 4 currently approved treatment options for patients with HER2-positive breast cancer and discussed how physicians could use the data to make treatment decisions in the adjuvant and neoadjuvant setting.
The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) will be tested as frontline therapy in previously untreated patients with mantle cell lymphoma as part of the 3-part phase 3 SYMPATICO trial.
In an interview with Targeted Oncology, Thomas M. Habermann, MD, reflects on the advancements he has observed in the treatment paradigm for lymphomas.
Compared to other racial and ethnic groups, Black patients were the least likely to receive chemotherapy or surgical resection for colorectal liver metastases and experienced worse survival
Uday R. Popat, MD, discusses the role of the JAK inhibitor ruxolitinib (Jakafi) as treatment of patients with graft-versus-host-disease.
Neeraj Agarwal, MD, reviews the case of a 73-year-old man with unresectable, locally advanced urothelial carcinoma and discusses latest data and treatment approaches.
As COVID-19 alters current approaches to caring for patients with cancer, early emerging research data reinforce what practicing oncologists have been observing in their patients are at increased risk of mortality.